Post

New research · Ophthalmology
Journal of current ophthalmology · 16h
Cohort studyJournal of current ophthalmology · 2025

Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study.

Saeed Karimi, Sadra Ashrafi, Seyyed Morteza Hosseini Imeni, Zahra Siavashpour
Read paper
OphthalmologyCohort study

Ruthenium-106 brachytherapy achieved tumor regression in all vasoproliferative tumor and hemangioma cases.

Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study.

Saeed Karimi … Zahra Siavashpour
Journal of current ophthalmology · 2025
Purpose

To evaluate the efficacy and safety of brachytherapy in patients with uveal melanoma and retinal vascular tumors.

Methods

Who received Ruthenium-106 (Ru-106) plaque brachytherapy at the Torfeh Medical Center between March 2016 and March 2022 were examined in this retrospective case-series.

n = 80 patients
Results

every eye tumor (vasoproliferative tumor and hemangioma) shrank after this radiation treatment

74.5%
Melanoma
100%
VPT/RCH
More results

Of the 80 patients, 55 had melanoma, 21 had vasoproliferative tumor (vasoproliferative tumor), and 4 had retinal capillary hemangioma (retinal capillary hemangioma).

Significant relationships were found between tumor characteristics, such as thickness and dose rate at the apex, and treatment outcomes.

More results

Complications included radiation retinopathy and cataract formation, with recurrence rates of 16.4% in melanoma and 7.7% in vasoproliferative tumor/retinal capillary hemangioma.

“
Conclusion · 1 of 3

Ru-106 plaque brachytherapy is effective in treating various intraocular tumors, particularly vasoproliferative tumor/retinal capillary hemangioma.

Conclusion · 2 of 3

Tumor thickness significantly influences treatment outcomes, emphasizing the need for tailored approaches in brachytherapy planning. However, small sample sizes for specific tumor types limited the generalization of the outcomes.

Conclusion · 3 of 3

Future research should focus on refining techniques and mitigating complications to improve patient outcomes in ocular oncology.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment